Bacterial cell wall enzyme is a possible drug target for treating infection
Breaching the armour of an attacking enemy is one way to take it down. For Neisseria meningitidis, the bacteria that causes the nervous system infection meningitis, this armour is the cell wall. Researchers investigate a key enzyme, LtgA, involved in building the cell wall to determine whether it could be a good target for weakening the bug. Bacteria were genetically altered to lack LtgA, have reduced levels or have a mutant version missing a region needed for proper function. Scanning electron microscopy revealed bacteria lacking LtgA (pictured, top right) or with reduced levels (bottom left) appeared largely the same as normal (top left). This is likely because other enzymes related to LtgA compensated for its absence or reduced levels. However, N.meningitidis with the mutant enzyme had deformed cell walls and struggled to grow and divide (bottom right). LtgA therefore holds promise as a novel drug target to treat meningitis.
Written by Lux Fatimathas
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.